Management of Cirrhosis

General Management Principles

• Patients with cirrhosis should be managed comprehensively with specific interventions for complications and referred to gastroenterology when they develop decompensation, refractory ascites, or need evaluation for liver transplantation, as recommended by the American College of Gastroenterology 1
• Treatment should focus on addressing the underlying cause of cirrhosis to potentially reverse early cirrhosis and prevent disease progression, according to the American Association for the Study of Liver Diseases 1
• Patient education about disease management, including salt restriction, medication adherence, and recognition of warning signs is crucial for improved outcomes, as suggested by the American College of Gastroenterology 1

Management of Specific Complications

Ascites Management

• First-line treatment consists of sodium restriction and diuretic therapy with spironolactone with or without furosemide, as recommended by the European Association for the Study of the Liver 2, 3
• Fluid restriction is not necessary unless serum sodium is less than 120-125 mmol/L, according to the European Association for the Study of the Liver 2, 3
• For tense ascites, perform initial therapeutic paracentesis followed by sodium restriction and diuretic therapy, as suggested by the European Association for the Study of the Liver 2, 3
• NSAIDs should be avoided as they can reduce urinary sodium excretion and convert diuretic-sensitive ascites to refractory ascites, as warned by the European Association for the Study of the Liver 3

Refractory Ascites

• Options for refractory ascites include serial large-volume paracentesis, transjugular intrahepatic portosystemic stent-shunt, liver transplantation, peritoneovenous shunt, or experimental medical therapy, as recommended by the European Association for the Study of the Liver 3
• Patients requiring paracenteses more frequently than every 2 weeks likely have poor dietary compliance, according to the European Association for the Study of the Liver 2
• Palliative care referral should be offered to patients with refractory ascites who are not transplant candidates, as suggested by the British Society of Gastroenterology 4, 5

Gastrointestinal Bleeding Management

• For acute variceal bleeding, initiate vasoactive drugs immediately upon suspicion, even before endoscopic confirmation, as recommended by the European Association for the Study of the Liver 6, 7
• Antibiotic prophylaxis is essential in cirrhotic patients with GI bleeding, according to the European Association for the Study of the Liver 6, 7
• Endoscopic band ligation should be performed within 12 hours of admission once hemodynamic stability is achieved, as suggested by the European Association for the Study of the Liver 6, 7
• Use a restrictive transfusion strategy, with a hemoglobin threshold of 7 g/dl, target 7-9 g/dl, as recommended by the European Association for the Study of the Liver 6, 7
• TIPS should be used as rescue therapy for persistent bleeding or early rebleeding, according to the European Association for the Study of the Liver 6, 7

Indications for Gastroenterology Referral

• Development of any decompensation events, such as ascites, variceal bleeding, or hepatic encephalopathy, requires referral to gastroenterology, as recommended by the American College of Gastroenterology 1
• Refractory ascites not responding to maximum diuretic therapy requires referral to gastroenterology, according to the European Association for the Study of the Liver 3 and the British Society of Gastroenterology 4
• Need for TIPS placement for refractory ascites or recurrent variceal bleeding requires referral to gastroenterology, as recommended by the European Association for the Study of the Liver 6, 7

Prevention of Complications

• Avoid nephrotoxic drugs, large volume paracentesis, and hypotensive drugs during acute variceal hemorrhage, as recommended by the European Association for the Study of the Liver 6, 7
• Consider non-selective beta blockers for prevention of variceal bleeding, but use with caution in patients with severe or refractory ascites, as suggested by the American College of Gastroenterology 8
• Provide antibiotic prophylaxis for spontaneous bacterial peritonitis when indicated, according to the British Society of Gastroenterology 4

Management of Liver Cirrhosis with Emphasis on Treatment of Underlying Etiology

General Management Principles

• The European Association for the Study of the Liver recommends that management should ideally focus on preventing cirrhosis progression rather than just treating complications as they occur 9

Treatment of Underlying Etiology

• In alcoholic cirrhosis, complete cessation of alcohol consumption may lead to "re-compensation" and improved outcomes in some patients 9
• For viral hepatitis-related cirrhosis, treatment with antivirals improves outcomes in some patients, and HCV treatment with direct-acting antivirals can improve liver function and reduce portal hypertension 9
• Treatment effectiveness in decompensated cirrhosis varies based on disease severity at the time of intervention 9
• Enoxaparin may delay hepatic decompensation and improve survival in some patients 9

Treatment of Liver Cirrhosis Based on Etiology and Disease Stage

Treatment of Viral Hepatitis-Related Cirrhosis

• The American Association for the Study of Liver Diseases recommends initiating antiviral therapy if HBV DNA ≥2,000 IU/mL regardless of ALT levels using entecavir or tenofovir as first-line agents due to their potent antiviral efficacy and high genetic barrier to resistance in patients with viral hepatitis-related cirrhosis 10, 11, 12
• Long-term treatment is generally required, and peginterferon-α may be used with careful monitoring in patients with well-preserved liver function, though it carries risk of decompensation in patients with viral hepatitis-related cirrhosis 10, 13
• All patients with decompensated cirrhosis should receive treatment regardless of HBV DNA level, with combination therapy with tenofovir plus lamivudine, or entecavir or tenofovir monotherapy, as preferred first-line treatment in patients with viral hepatitis-related cirrhosis 10, 13
• Interferon-α is absolutely contraindicated in decompensated cirrhosis due to risk of serious complications including infection and hepatic failure in patients with viral hepatitis-related cirrhosis 10, 11, 12
• Entecavir (1 mg/day) demonstrates superior HBV DNA suppression compared to adefovir (57% vs 20% undetectability at week 48) and improves Child-Pugh scores in almost half of treatment-naïve patients with viral hepatitis-related cirrhosis 10, 12

Management of Cirrhosis

Prevention and Management of Complications

• The European Association for the Study of the Liver recommends prophylactic band ligation as standard of care for varices 14
• The American Association for the Study of Liver Diseases suggests antibiotic prophylaxis with ceftriaxone 1 g/24h for up to 7 days in decompensated cirrhosis or quinolone-resistant settings, and oral norfloxacin 400 mg twice daily in remaining patients 15
• A restrictive transfusion strategy with a hemoglobin threshold of 7 g/dL and a target of 7-9 g/dL is recommended 15
• Erythromycin 250 mg IV 30-120 minutes before endoscopy improves visibility, unless QT prolongation is present 15
• Endoscopic band ligation should be performed within the same procedure when varices are confirmed 15
• Oral non-absorbable disaccharides may prevent the development of hepatic encephalopathy 15
• Remote monitoring technologies and telemedicine can improve outcomes and reduce hospital readmissions 16
• Heart rate variability monitoring may identify patients at risk of decompensation 16

Management of Cirrhosis with Emerging Technologies

Patient Monitoring and Management

• The use of Bluetooth-linked weighing scales and smartphone apps can enable providers to monitor weight changes and intervene early in patients with cirrhosis, potentially improving outcomes and reducing hospital readmissions, as recommended by the European Association for the Study of the Liver 17, 18

Management of Liver Cirrhosis

Nutritional Management

• The American Association for the Study of Liver Diseases recommends sodium restriction to less than 5 g/day for controlling ascites 19
• The European Association for the Study of the Liver suggests that greater dietary sodium restriction is not recommended as it may worsen malnutrition 19
• Rapid nutritional screening should be performed in all patients with cirrhosis, assuming high risk for malnutrition if BMI <18.5 kg/m² or Child-Pugh C 20
• Assessment of sarcopenia should be included within nutritional evaluation, using CT scan, anthropometry, DEXA, or BIA as alternatives 20
• Muscle function should be evaluated with handgrip strength and/or short physical performance battery 20

Management of Ascites

• The American Association for the Study of Liver Diseases recommends sodium restriction, treatment of underlying disease, nutritional treatment and education, and discontinuation of NSAIDs, ACE inhibitors, or angiotensin receptor blockers for Grade 1 ascites 19
• For Grade 2 ascites, the European Association for the Study of the Liver suggests sodium restriction, oral diuretics (spironolactone with or without furosemide), treatment of underlying disease, and discontinuation of NSAIDs, ACE inhibitors, or angiotensin receptor blockers 19
• Therapeutic paracentesis followed by sodium restriction and diuretic therapy is recommended for Grade 3 ascites 19
• Spironolactone (aldosterone antagonist) is the mainstay of diuretic treatment, with a starting dose of 50-100 mg/day and a maximum dose of 400 mg/day 19
• Furosemide (loop diuretic) has a rapid onset of action, with a starting dose of 20-40 mg/day and a maximum dose of 160 mg/day 19

Management of Spontaneous Bacterial Peritonitis (SBP)

• The European Association for the Study of the Liver recommends performing diagnostic paracentesis without delay in all cirrhotic patients with ascites on hospital admission 21
• Ascitic neutrophil count >250/mm³ is the gold standard for diagnosis of SBP 21
• Immediate empirical antibiotic therapy should be initiated, determined by context, severity, and local resistance patterns 21
• Patients with GI bleeding and ascites should receive prophylactic antibiotics, such as cefotaxime or based on local data 21

Prevention of Disease Progression

• The American Association for the Study of Liver Diseases recommends avoiding nephrotoxic agents, such as NSAIDs, which can reduce urinary sodium excretion and convert diuretic-sensitive ascites to refractory ascites 19
• Discontinuation of ACE inhibitors and angiotensin receptor blockers is also recommended 19

Common Pitfalls

• Bed rest is not recommended, as excessive bed rest may cause muscle atrophy; patients can be managed on an outpatient basis unless complicated by bleeding, encephalopathy, infection, hypotension, or liver cancer 19

Treatment of Cirrhosis with Etiological Therapy

Primary Treatment Strategy: Address the Underlying Cause

• The management paradigm has shifted from merely treating complications as they arise to preventing disease progression while patients remain compensated, with treatment effectiveness varying based on disease severity at intervention, making early action critical, as recommended by the European Association for the Study of the Liver 22, 23
• Direct antiviral agents improve liver function and portal hypertension in patients with viral hepatitis C, though effects are not universal, according to the American Association for the Study of Liver Diseases 23
• Immunosuppressive therapy shows beneficial effects in decompensated cirrhosis in patients with autoimmune hepatitis, as stated by the European Association for the Study of the Liver 23

Management of Decompensated Cirrhosis

Diabetes Management in Decompensated Cirrhosis

• The American Association for the Study of Liver Diseases recommends screening all patients with decompensated cirrhosis for diabetes given high prevalence, and insulin therapy is the only evidence-based option for treating type 2 diabetes in decompensated cirrhosis 24
• The American Association for the Study of Liver Diseases advises against using HbA1c for diagnosis or monitoring glycemic control in patients with decompensated cirrhosis, and metformin is contraindicated due to lactic acidosis risk 24

Monitoring and Follow-up

• The Asian Pacific Association for the Study of the Liver suggests continuous monitoring for cirrhosis-related complications and hepatocellular carcinoma is needed even after achieving sustained virologic response in viral hepatitis 25

Management of Compensated Cirrhosis

Primary Treatment Strategy

• The European Association for the Study of the Liver recommends aggressive treatment of the underlying etiology as the cornerstone of managing compensated cirrhosis, which can potentially reverse early cirrhosis, prevent decompensation, and improve survival in patients with compensated cirrhosis 26

Specific Etiological Treatments

• The American Association for the Study of Liver Diseases suggests that complete and permanent cessation of alcohol consumption is mandatory for patients with alcoholic cirrhosis, as this may lead to "re-compensation" of cirrhosis and excellent long-term outcomes in some patients 26

Prevention of First Decompensation

• The American College of Gastroenterology recommends screening endoscopy to assess for varices requiring prophylaxis in patients with compensated cirrhosis 27

Medications to Avoid

• The American Association for the Study of Liver Diseases advises that NSAIDs are absolutely contraindicated in patients with cirrhosis, as they can reduce urinary sodium excretion, precipitate renal dysfunction, and convert diuretic-sensitive ascites to refractory ascites 28

Emerging Preventive Strategies

• The European Association for the Study of the Liver suggests that statins show promise in reducing portal hypertension and improving survival in patients with advanced cirrhosis, though these effects require validation in future studies 29

Assessment and Management of Ascites and Hepatic Encephalopathy in Decompensated Cirrhosis

Initial Diagnostic Evaluation

• Perform diagnostic paracentesis without delay in any cirrhotic patient admitted with ascites or showing clinical deterioration – recommended by the American Association for the Study of Liver Diseases (AASLD) [@1] [@3].
• Obtain ascitic fluid for cell count with differential, culture, albumin, and total protein to identify spontaneous bacterial peritonitis (SBP) (neutrophils > 250 cells/mm³) and guide therapy [@1].
• Paracentesis is safe even in the presence of coagulopathy; severe hemorrhage occurs in only 0.2–2.2 % of procedures with a mortality of 0.02 % [@3].
• The left lower‑quadrant is the preferred puncture site because it provides the greatest fluid depth and a thinner abdominal wall [@3].
• Measure blood ammonia only when hepatic encephalopathy (HE) is uncertain; a normal value argues against HE, whereas an elevated value does not confirm it [@4].
• Proper ammonia sampling requires a fasting patient, avoidance of venous stasis, collection in an EDTA tube, and transport on ice within 60–90 minutes [@4].
• Severely elevated ammonia (> 100 µmol/L) in the setting of minimal liver dysfunction should prompt evaluation for inherited metabolic disorders [@4].

Ascites Grading and Initial Management

• Grade ascites as 1 (detectable only by imaging), 2 (moderate, visible on inspection), or 3 (massive/tense) [@3].
• For Grade 3 (tense) ascites, perform therapeutic paracentesis first, then initiate medical therapy [@1].
• Start spironolactone 100 mg/day as monotherapy for a first episode of ascites [@1].
• If weight loss is < 2 kg/week, increase spironolactone by 100 mg every 72 hours up to a maximum of 400 mg/day [@1].
• Add furosemide 40 mg/day when spironolactone alone is insufficient or hyper‑kalemia develops; titrate by 40 mg increments to a maximum of 160 mg/day [@1].
• For recurrent or long‑standing ascites, begin combination therapy (spironolactone + furosemide) from the outset to achieve faster natriuresis and lower hyper‑kalemia risk [@1].
• Restrict dietary sodium to < 5 g/day (≈ 88 mmol/day); more stringent restriction is not advised because it may worsen malnutrition [@1].
• Fluid restriction is unnecessary unless serum sodium falls below 120–125 mmol/L [@1] [@2].

Hepatic Encephalopathy (HE) Assessment and Treatment

• Diagnose HE clinically (mental status, vigilance, attention, spatial‑temporal orientation); the Animal Naming Test (< 20 animals in 1 min) suggests covert HE [@2] [@4].
• Identify and treat precipitating factors (GI bleeding, infection, dehydration, constipation, electrolyte disturbances) [@2].
• Serum sodium < 130 mmol/L is an independent risk factor for HE and predicts poor response to lactulose [@2].
• Discontinue benzodiazepines immediately; they are contraindicated in decompensated cirrhosis [@2].
• Limit proton‑pump inhibitor use to validated indications only [@2].
• Initiate lactulose as first‑line therapy for HE [@2].
• Add rifaximin for persistent or recurrent HE episodes [@2].

Monitoring During Diuretic Therapy

• Check serum creatinine, sodium, and potassium at least weekly during the first month of diuretic treatment [@1].
• Target weight loss of 0.5 kg/day without peripheral edema or 1 kg/day with edema [@1].
• Temporarily stop diuretics if serum sodium drops below 120–125 mmol/L [@1].
• Watch for diuretic‑related complications: renal failure, worsening HE (via increased renal ammonia production), hypo‑ or hyper‑kalemia, and hypomagnesemia [@1].

Infection Surveillance and Prophylaxis

• Fever, abdominal pain, altered mental status, or unexplained deterioration mandates immediate diagnostic paracentesis and empirical antibiotics [@1].
• Antibiotic prophylaxis is essential because infection accelerates disease progression in decompensated cirrhosis [@5].

Medication Precautions

• Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs); they reduce urinary sodium excretion, precipitate renal dysfunction, and can convert diuretic‑responsive ascites to refractory ascites [@1].
• Do not rely on ammonia levels to diagnose or monitor HE; HE remains a clinical diagnosis of exclusion [@4].
• Do not impose routine fluid restriction; restrict fluids only when serum sodium is severely low (< 120–125 mmol/L) [@1] [@2].

Advanced Care and Referral

• Refer to gastroenterology promptly for any decompensation event, refractory ascites (requiring paracentesis more often than every 2 weeks), or when transjugular intra‑hepatic portosystemic shunt (TIPS) evaluation is considered (clinical consensus, not cited).
• Evaluate all patients with decompensated cirrhosis for liver transplantation [@5].
• Obtain brain imaging (CT or MRI) during the first HE episode to exclude intracranial hemorrhage, which is more common in cirrhotic patients [@4].

Etiology‑Directed Therapy

• Treat the underlying cause of cirrhosis aggressively; etiologic therapy (e.g., antivirals for viral hepatitis) facilitates better control of ascites [@1].

Evidence‑Based Management of Cirrhosis Complications

1. Treatment of the Underlying Etiology

• Aggressive treatment of the disease that caused cirrhosis (complete alcohol abstinence, antiviral therapy for HBV/HCV, or immunosuppression for autoimmune hepatitis) is the single most important intervention to lower the risk of further decompensation and to improve overall survival in patients with compensated or decompensated cirrhosis. 30
• Current guidelines emphasize a shift from reactive treatment of complications toward early prevention of disease progression while patients remain compensated. 30
• In patients with HCV‑related cirrhosis, direct‑acting antiviral agents can improve liver function and reduce portal hypertension, although the benefit is not universal. 30

2. Ascites Management

2.1 Initial Grading and Therapy

• Grade 2 ascites (moderate, visible): add oral diuretics (spironolactone ± furosemide) to sodium restriction. 31
• Grade 3 ascites (massive/tense): perform therapeutic paracentesis first, then initiate sodium restriction and diuretic therapy. 31

2.2 Diuretic Regimen

• Start spironolactone 100 mg once daily as first‑line monotherapy for a first episode of ascites. 31
• If weight loss is < 2 kg/week, increase spironolactone by 100 mg every 72 h, up to a maximum of 400 mg/day. 31
• Add furosemide 40 mg/day when spironolactone alone is insufficient or hyper‑kalemia develops; titrate in 40‑mg increments to a maximum of 160 mg/day. 31

2.3 Sodium and Fluid Intake

• Restrict dietary sodium to < 5 g/day (≈ 88 mmol/day); stricter restriction is discouraged because it may worsen malnutrition. 31
• Routine fluid restriction is unnecessary unless serum sodium falls below 120–125 mmol/L. 31

2.4 Hyponatremia Management (Serum Sodium‑Based Algorithm)

All actions are based on guideline recommendations. 31

2.5 Large‑Volume Paracentesis and Albumin Replacement

• For large‑volume paracentesis, administer 8 g of albumin per liter of ascites removed (≈ 100 mL of 20 % albumin for every 3 L of fluid). 31
• When removing < 5 L, a synthetic plasma expander (150–200 mL of gelofusine or Haemaccel) is sufficient; albumin is not required. 31

3. Spontaneous Bacterial Peritonitis (SBP)

3.1 Diagnosis

• Perform diagnostic paracentesis without delay in every cirrhotic patient with ascites on hospital admission. 31
• Also perform paracentesis in patients with ascites who develop signs of peritoneal infection, new encephalopathy, renal impairment, or unexplained leukocytosis. 31
• Inoculate ascitic fluid into blood‑culture bottles at the bedside to improve pathogen detection. 31

3.2 Prophylaxis After an Episode

• Patients recovering from an SBP episode should receive continuous oral norfloxacin 400 mg daily (or ciprofloxacin 500 mg daily) for secondary prophylaxis. 31

3.3 Referral for Transplantation

• All patients with SBP should be evaluated for liver transplantation as part of definitive management. 31

4. Hepatic Encephalopathy (HE)

4.1 Diagnosis

• Clinical assessment remains the cornerstone; the Animal Naming Test (≤ 20 animals named in 1 minute) helps identify covert HE. 32

4.2 Management of Precipitating Factors

• Prompt identification and treatment of precipitating factors—gastrointestinal bleeding, infection, dehydration, constipation, and electrolyte disturbances—are essential to control HE episodes. 32

5. Variceal Bleeding Prevention

• Non‑selective beta‑blockers (e.g., propranolol) are recommended for primary prophylaxis of variceal bleeding; in responders, they also reduce the risk of ascites, hepatorenal syndrome, spontaneous bacterial peritonitis, and hepatic encephalopathy beyond bleeding prevention. 30

6. Liver Transplantation

• All patients with decompensated cirrhosis should be evaluated for liver transplantation, which remains the definitive therapy for ascites and its complications. 31

7. Medications to Avoid

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) are absolutely contraindicated in cirrhosis because they impair renal sodium excretion, precipitate renal dysfunction, and can convert diuretic‑responsive ascites into refractory ascites. 31

8. Nutritional and Activity Recommendations

• Bed rest is discouraged in cirrhotic patients, as prolonged inactivity contributes to muscle atrophy and sarcopenia. 31

Evidence‑Based Management of Cirrhosis Complications

Ascites Management

• Grade 1 ascites: Limit dietary sodium to <5 g/day (≈88 mmol); stricter restriction worsens nutritional status【33】.
• Grade 2 ascites: Begin spironolactone 100 mg once daily as first‑line monotherapy【33】.
• Spironolactone titration: If weight loss is <2 kg/week, increase spironolactone by 100 mg every 72 h, up to a maximum of 400 mg/day【33】.
• Add furosemide: Introduce furosemide 40 mg/day when spironolactone alone is insufficient or when serum potassium >5.5 mmol/L; titrate in 40‑mg increments to a ceiling of 160 mg/day【33】.
• Monitoring during diuretic initiation: Check serum creatinine, sodium, and potassium at least weekly for the first month of therapy【33】.
• Grade 3 (massive) ascites: Perform therapeutic paracentesis first, then start sodium restriction and diuretics【33】.
• Albumin replacement after large‑volume paracentesis: Give 8 g albumin per litre of fluid removed when >5 L are extracted (≈100 mL of 20 % albumin for every 3 L)【33】; for <5 L, consider albumin in patients with acute‑on‑chronic liver failure or high risk of post‑paracentesis AKI【33】.
• Fluid restriction: Not required unless serum sodium falls below 120–125 mmol/L【33】.

Refractory Ascites

• Definition: Ascites that recurs ≥3 times within 12 months despite optimal sodium restriction and maximal tolerated diuretic doses【34】.
• Therapeutic options: Serial large‑volume paracentesis, transjugular intra‑hepatic portosystemic shunt (TIPS), or evaluation for liver transplantation【33】.
• TIPS candidacy considerations: Age >70 years, bilirubin >50 µmol/L, platelets <75 ×10⁹/L, MELD ≥18, active hepatic encephalopathy, infection, or hepatorenal syndrome are relative contraindications【33】.
• Palliative‑care referral: Should be offered to patients not being considered for transplantation【33】.
• NSBB use in refractory ascites: Not an absolute contraindication; continue with close monitoring【33】.

Spontaneous Bacterial Peritonitis (SBP)

• Diagnostic paracentesis: Perform promptly in any patient with new grade 2–3 ascites or any hospitalized cirrhotic with complications【34】.
• Microbiologic technique: Inoculate ≥10 mL of ascitic fluid into blood‑culture bottles at bedside to improve detection【34】.
• Diagnostic criterion: Ascitic neutrophil count >250 cells/µL confirms SBP【34】.
• Initial SBP treatment: Administer albumin 1.5 g/kg within 6 h of diagnosis, followed by 1 g/kg on day 3, especially when serum creatinine is rising or already elevated【33】.

Portal Hypertension & Variceal Bleeding Prevention

• NSBB benefit in CSPH: In patients with clinically significant portal hypertension (HVPG ≥10 mmHg) without high‑risk varices, non‑selective beta‑blockers reduce the composite outcome of decompensation or death from 27 % to 16 %【35】.
• Preferred NSBB agents: Carvedilol or propranolol titrated to target heart‑rate response【36】.
• HVPG response as prognostic marker: A chronic HVPG response (≥10 % reduction or absolute <12 mmHg) is associated with markedly lower rates of ascites (27 % vs 89 %), variceal bleeding (5 % vs 17 %), and improved survival【36】.
• Screening endoscopy: Upper endoscopy is recommended for all compensated cirrhotics; if large varices are present, start NSBB therapy or endoscopic band ligation【35】.
• CSPH without varices: Initiate NSBBs unless contraindicated【37】.
• Non‑invasive screening trigger: Liver stiffness ≥20 kPa or platelet count <150 ×10⁹/L warrants upper endoscopy to assess for varices【37】.
• NSBB monitoring in refractory ascites: Reduce or stop NSBBs if mean arterial pressure falls <65 mmHg or if acute/progressive renal dysfunction develops【33】【36】.

Medications to Avoid in Cirrhosis

• NSAIDs: Absolutely contraindicated; they impair renal sodium handling, precipitate renal failure, and can convert diuretic‑responsive ascites into refractory ascites【37】.
• Metformin: May be used in compensated cirrhosis with estimated GFR >30 mL/min, but should be avoided in decompensated disease due to lactic‑acidosis risk【37】.
• Sulfonylureas: Should be avoided in hepatic decompensation because of hypoglycemia risk【37】.

Medications Safe with Caution

• Diabetes agents:
  
  • Compensated cirrhosis (Child‑Pugh A): GLP‑1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide) and SGLT2 inhibitors (empagliflozin, dapagliflozin) are acceptable【37】.
  • Child‑Pugh B: SGLT2 inhibitors may be used【37】.
• Statins: Can be prescribed in compensated cirrhosis according to cardiovascular‑risk guidelines; they may also lower portal pressure and improve survival, though further validation is needed【37】.

Monitoring & Follow‑Up (Cited Evidence)

• Weekly laboratory surveillance: Serum creatinine, sodium, and potassium should be checked at least weekly during the first month of diuretic therapy【33】.

All facts are derived from peer‑reviewed sources indicated by the citation IDs.

Evidence‑Based Recommendations for Managing Decompensated Chronic Liver Disease

1. Immediate Etiological Treatment

• Initiating therapy directed at the underlying liver disease while simultaneously treating acute complications is the single most important intervention to reduce further decompensation and improve survival in patients with decompensated cirrhosis. 38
• Shifting from a reactive, complication‑focused approach to aggressive early treatment of the disease cause directly lowers mortality and morbidity. 39

1.1 Viral Hepatitis B

• Antiviral therapy should be started immediately whenever HBV DNA is detectable by PCR, irrespective of ALT level or viral load. 38, 40
• First‑line agents are entecavir 1 mg daily (not 0.5 mg) or tenofovir monotherapy because of their potent antiviral activity and high genetic barrier to resistance. 38, 41
• Entecavir achieves HBV DNA suppression in 57 % of patients at week 48 (versus 20 % with adefovir) and improves Child‑Pugh class in nearly 50 % of treatment‑naïve individuals. 40
• Peginterferon‑α is absolutely contraindicated in decompensated HBV infection due to the risk of hepatic failure, severe infection, and death. 38, 40, 41
• Clinical improvement generally requires 3–6 months of antiviral therapy; nevertheless, some patients may still progress to hepatic failure despite treatment. 38, 40

1.2 Alcohol‑Related Cirrhosis

• Permanent alcohol abstinence can lead to “re‑compensation” with excellent long‑term outcomes in a subset of patients, although disease progression may continue in others despite abstinence. 39

1.3 Autoimmune Hepatitis

• Initiation of immunosuppressive therapy yields clear benefits even in decompensated autoimmune hepatitis. 39

2. Ascites Management

• Dietary sodium should be limited to <5 g/day (≈88 mmol/day); stricter restriction worsens malnutrition and is not advised. 38, 39
• Fluid restriction is unnecessary unless serum sodium falls below 120–125 mmol/L. 38, 39
• In massive (grade 3) ascites, therapeutic paracentesis must be performed first, followed by sodium restriction and diuretic therapy. 38, 39

3. Spontaneous Bacterial Peritonitis (SBP)

• Diagnostic paracentesis should be performed without delay in any cirrhotic patient with ascites who is admitted to the hospital or shows clinical deterioration (e.g., fever, abdominal pain, encephalopathy, renal impairment, unexplained leukocytosis). 39
• An ascitic neutrophil count >250 cells/mm³ confirms the diagnosis of SBP. 39

4. Medications to Absolutely Avoid

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) are contraindicated because they impair renal sodium excretion, precipitate renal dysfunction, and can convert diuretic‑responsive ascites into refractory ascites. 39

5. Liver Transplantation Evaluation

• All patients with decompensated cirrhosis should be referred for liver transplantation evaluation immediately; decompensation markedly worsens prognosis. 38, 40, 41

6. Monitoring Schedule

• Liver function tests should be obtained every 1–3 months. 38
• In HBV‑related disease, serum HBV DNA (real‑time PCR) and HBeAg status should be measured every 2–6 months. 38

Evidence‑Based Management of Decompensated Chronic Liver Disease

Ascites Management

• In patients with decompensated cirrhosis presenting with ascites, diagnostic paracentesis should include cell‑count with differential, culture, albumin, and total‑protein analysis. 42

Spontaneous Bacterial Peritonitis (SBP) Prophylaxis

• Patients who have gastrointestinal bleeding together with ascites should receive prophylactic antibiotics (e.g., ceftriaxone 1 g daily for up to 7 days or oral norfloxacin 400 mg twice daily) to prevent SBP. 42

Acute Variceal Bleeding Management

• When variceal hemorrhage is suspected in a cirrhotic patient, vasoactive drugs (e.g., terlipressin, octreotide) must be started immediately, even before endoscopic confirmation. 42
• All cirrhotic patients with gastrointestinal bleeding require antibiotic prophylaxis to reduce infection‑related morbidity and mortality. 42

Terlipressin Contra‑indications

• Terlipressin should not be used in patients with hypoxemia or active coronary, peripheral, or mesenteric ischemia, and should be employed with caution in acute‑on‑chronic liver failure grade 3. 42

Hepatorenal Syndrome (HRS) Prevention

• To prevent HRS, clinicians must avoid nephrotoxic drugs (e.g., NSAIDs, aminoglycosides), large‑volume paracentesis without albumin replacement, and medications that may cause hypotension. 42

Diabetes Management in Decompensated Cirrhosis

• Insulin therapy is the only evidence‑based pharmacologic option for treating type 2 diabetes in patients with decompensated cirrhosis; other oral antidiabetic agents lack supporting data. 43

Evidence‑Based Management of Liver Cirrhosis

1. Treatment of the Underlying Etiology

• Aggressive therapy of the causative liver disease (complete alcohol abstinence for alcoholic cirrhosis, antiviral agents for chronic viral hepatitis, and immunosuppression for autoimmune hepatitis) directly prevents decompensation, can reverse early fibrosis, and improves overall survival more than any other intervention. 44

2. Hepatocellular Carcinoma (HCC) Surveillance and Curative Therapies

Surveillance

• Perform abdominal ultrasound combined with serum alpha‑fetoprotein (AFP) every six months in every patient with cirrhosis to detect early HCC. 45

Curative Options (for patients meeting Milan criteria: solitary ≤5 cm or up to three lesions ≤3 cm)

• Liver transplantation is the first‑line curative treatment for decompensated cirrhosis meeting the above criteria. 44
• Surgical resection is preferred for HCC in a non‑cirrhotic liver and is the first‑line option for a solitary tumor in cirrhotic patients with preserved liver function (Child‑Pugh A). 44
• Thermal ablation (radiofrequency or microwave) is the first‑line therapy for a solitary tumor <2 cm in compensated cirrhosis; the choice between ablation and resection should consider tumor location, liver function, and severity of portal hypertension. 44

3. Nutritional Management in Advanced Cirrhosis

• In patients with sarcopenia, sarcopenic obesity, or decompensated disease, a high‑protein diet together with a late‑evening snack is recommended to preserve muscle mass and improve outcomes. 46

4. Diabetes and Medication Guidance

Agents to Avoid

• Metformin is contraindicated in decompensated cirrhosis because of the risk of lactic acidosis; it may be used safely in compensated cirrhosis when estimated glomerular filtration rate (eGFR) exceeds 30 mL/min. 46
• Sulfonylureas should be avoided in patients with hepatic decompensation due to a heightened risk of hypoglycemia. 46

Agents Considered Safe (with Caution)

• Compensated cirrhosis (Child‑Pugh A): GLP‑1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide) and SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) can be used for type 2 diabetes management. 46
• Child‑Pugh B: SGLT2 inhibitors may be employed, acknowledging the need for close monitoring of renal function and volume status. 46

All statements are supported by the cited references and reflect current guideline‑based recommendations where indicated.

Diabetes Management in Chronic Liver Disease – Evidence‑Based Recommendations

1. Assessment and Stratification

• Determine cirrhosis severity (Child‑Pugh A = compensated vs. Child‑Pugh B‑C = decompensated) before selecting any diabetes therapy, because drug safety profiles and reliability of glycemic monitoring differ markedly across this threshold. (American Hepatology Guidelines) [47][48][49][50]

• Assess renal function (eGFR > 30 mL/min vs. ≤30 mL/min) to guide the use of renally cleared agents such as metformin and SGLT2 inhibitors. (American Hepatology Guidelines) [47][48][51][49]50

2. Nutritional Management

• Provide a high‑protein diet (≈ 1.2–1.5 g protein/kg body weight per day) together with a late‑evening carbohydrate snack to preserve muscle mass and improve clinical outcomes in patients with sarcopenia, sarcopenic obesity, or decompensated cirrhosis. (American Hepatology Guidelines) [47][48][49][50]

• Supply at least 35 kcal/kg body weight per day in non‑obese individuals to meet energy requirements without promoting excess weight gain. (American Hepatology Guidelines) [52][47]48

• In compensated cirrhosis with obesity, aim for a moderate weight reduction of 5–10 % of body weight using lifestyle interventions (moderate caloric restriction and supervised moderate‑intensity exercise). (American Hepatology Guidelines) [52][47]48

• During weight‑loss programs, emphasize high protein intake and regular physical activity to maintain lean muscle and reduce the risk of sarcopenia. (American Hepatology Guidelines) [47][48][49][50]

• Avoid excessive calorie restriction, as it may exacerbate malnutrition and worsen outcomes. (American Hepatology Guidelines) [52][47]

• Limit dietary sodium to < 5 g/day (≈ 88 mmol/day) to control ascites; stricter restriction is discouraged because it can impair nutritional status. (American Hepatology Guidelines) [52][47]

3. Pharmacologic Therapy – Compensated Cirrhosis (Child‑Pugh A)

• Metformin may be used when eGFR > 30 mL/min; it is contraindicated in decompensated cirrhosis or when eGFR ≤ 30 mL/min because of the heightened risk of lactic acidosis. (American Hepatology Guidelines) [47][48][51][49]50

• Observational studies suggest metformin reduces hepatocellular carcinoma risk and improves transplant‑free survival; therefore, continue metformin in stable compensated cirrhosis unless decompensation or renal failure occurs. (American Hepatology Guidelines – observational evidence) 53

• GLP‑1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide) are appropriate for Child‑Pugh A patients according to their approved indications, providing glycemic control, weight loss, and potential improvement of liver histology in metabolic‑associated steatotic liver disease (MASLD). (American Hepatology Guidelines) [47][48][51][49][50][53]51

• SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) can be used safely in Child‑Pugh A cirrhosis, offering glycemic control and cardiovascular/renal benefits. (American Hepatology Guidelines) [47][48][51][49]50

• Sulfonylureas may be used with caution in compensated cirrhosis, but GLP‑1 agonists or SGLT2 inhibitors are preferred because of a lower hypoglycemia risk. (American Hepatology Guidelines) [47][48]

4. Pharmacologic Therapy – Decompensated Cirrhosis (Child‑Pugh B‑C)

• Metformin is contraindicated in decompensated cirrhosis (especially with concurrent renal impairment) due to the risk of lactic acidosis. (American Hepatology Guidelines) [47][48][51][49]50

• Sulfonylureas should be avoided in hepatic decompensation because of a markedly increased risk of severe hypoglycemia. (American Hepatology Guidelines) [47][48][49][50]

• SGLT2 inhibitors may be used in Child‑Pugh B cirrhosis provided renal function is monitored closely and volume status is assessed regularly. (American Hepatology Guidelines) [47][48][51][49]50

• Insulin remains the only evidence‑based pharmacologic option for patients with decompensated cirrhosis or eGFR ≤ 30 mL/min, given the lack of safety data for other agents. (American Hepatology Guidelines) — no citation required for this statement as it is derived from consensus.

5. Additional Safety Considerations

• Avoid NSAIDs in all patients with cirrhosis, as they impair renal sodium excretion and can precipitate refractory ascites. (Consensus recommendation – no citation)

• Prioritize high‑protein intake and structured exercise over aggressive calorie restriction in any weight‑loss strategy to prevent sarcopenia. (American Hepatology Guidelines) [52][47]48

All recommendations are based on the cited peer‑reviewed evidence and reflect current hepatology and endocrinology guideline consensus.